Volume 14 Issue 4
Jul.  2023
Turn off MathJax
Article Contents
LUO Yaping, LI Fang. Current Status and Future Prospects of Theranostics with Radiopharmaceuticals[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 669-672. doi: 10.12290/xhyxzz.2023-0236
Citation: LUO Yaping, LI Fang. Current Status and Future Prospects of Theranostics with Radiopharmaceuticals[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 669-672. doi: 10.12290/xhyxzz.2023-0236

Current Status and Future Prospects of Theranostics with Radiopharmaceuticals

doi: 10.12290/xhyxzz.2023-0236
More Information
  • Corresponding author: LI Fang, E-mail: lifang@pumch.cn
  • Received Date: 2023-05-14
  • Accepted Date: 2023-07-18
  • Available Online: 2023-07-20
  • Publish Date: 2023-07-30
  • Nuclear medicine is a novel technique of theranostics that uses radiopharmaceuticals. Nuclear medicine dated back to a century ago. Owing to the development of nuclear medicine devices and radiopharmaceuticals, increasing clinical demand, government support, and global cooperations, nuclear medicine has witnessed a rapid development. Nowadays, nuclear medicine has played an important and unique role in diagnosis and therapy. There are opportunities and challenges in future development of nuclear medicine, and more progress will be made in nuclear medicine imaging, radionuclide therapy, and artificial intelligence.
  • loading
  • [1] Carlsson S. A glance at the history of nuclear medicine[J]. Acta Oncol, 1995, 34: 1095-1102. doi:  10.3109/02841869509127236
    [2] Middlebrooks JT. A Half-Century of Nuclear Medicine[J]. J Nucl Med Technol, 2020, 48: 40S-42S. doi:  10.2967/jnmt.119.233486
    [3] Hutton BF. The origins of SPECT and SPECT/CT[J]. Eur J Nucl Med Mol Imaging, 2014, 41: S3-S16. doi:  10.1007/s00259-013-2606-5
    [4] Verburg FA, Heinzel A, Hänscheid H, et al. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 199-201. doi:  10.1007/s00259-013-2609-2
    [5] Zimmerman RE. Gamma cameras-state of the art[J]. Med Instrum, 1979, 13: 161-164.
    [6] Wagner HN Jr. A brief history of positron emission tomography (PET)[J]. Semin Nucl Med, 1998, 28: 213-220. doi:  10.1016/S0001-2998(98)80027-5
    [7] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi:  10.1056/NEJMoa1607427
    [8] Fallah J, Agrawal S, Gittleman H, et al. FDA Approval Summary: Lutetium Lu(177) Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer[J]. Clin Cancer Res, 2023, 29: 1651-1657. doi:  10.1158/1078-0432.CCR-22-2875
    [9] Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium[J]. Thyroid, 2019, 29: 7-26. doi:  10.1089/thy.2017.0129
    [10] Singh S, Hope TA, Bergsland EB, et al. Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting[J]. J Natl Cancer Inst, 2023. doi:  10.1093/jnci/djad096.
    [11] Ferretti S, Mercinelli C, Marandino L, et al. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs[J]. Res Rep Urol, 2023, 15: 243-259.
    [12] Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step[J]. Nucl Med Commun, 2009, 30: 5-15. doi:  10.1097/MNM.0b013e328313e565
    [13] Voutsinas N, Lekperic S, Barazani S, et al. Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques[J]. J Nucl Med, 2018, 59: 1649-1654. doi:  10.2967/jnumed.116.186346
    [14] Velikyan I. Prospective of (68)Ga-radiopharmaceutical development[J]. Theranostics, 2013, 4: 47-80.
    [15] Velikyan I. Continued rapid growth in (68) Ga applications: update 2013 to June 2014[J]. J Labelled Comp Radiopharm, 2015, 58: 99-121. doi:  10.1002/jlcr.3250
    [16] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. doi:  10.1056/NEJMoa2107322
    [17] Cheng X, Li F, Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress[J]. Curr Oncol, 2022, 29: 7868-7886. doi:  10.3390/curroncol29100622
    [18] Yordanova A, Ahmadzadehfar H. Combination Therapies with PRRT[J]. Pharmaceuticals (Basel), 2021, 14: 1005. doi:  10.3390/ph14101005
    [19] Nensa F, Demircioglu A, Rischpler C. Artificial Intelligence in Nuclear Medicine[J]. J Nucl Med, 2019, 60: 29S-37S. doi:  10.2967/jnumed.118.220590
    [20] Seifert R, Weber M, Kocakavuk E, et al. Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives[J]. Semin Nucl Med, 2021, 51: 170-177. doi:  10.1053/j.semnuclmed.2020.08.003
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1999) PDF downloads(443) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint